Community Pharmacy England (CPE) has notified pharmacy teams that starting 1 August 2024, three Hormone Replacement Therapy (HRT) medicines will be
discontinued and will no longer be covered under the NHS HRT Prescription Prepayment Certificate (HRT PPC) scheme.
These are Bedol® 2mg tablets, Climanor® 5mg tablets and Clinorette® tablets.
Since Climanor® 5mg tablets have been discontinued, Medroxyprogesterone 5mg tablets will also be removed from the HRT PPC list, as this generic product is no
longer available as a licensed HRT medicine.
The CPE also noted that Provera® 5mg tablets, being an unlicensed HRT medicine, are not covered by the HRT PPC.
Pharmacy staff are advised to check the NHS Business Services Authority (NHSBSA) website for the most current list of HRT medicines covered by the HRT PPC.
The CPE has updated its HRT PPC medicines list to reflect these changes, which will also be updated in Part XVI of the August 2024 Drug Tariff.
The Department of Health and Social Care (DHSC) has included Tibolone 2.5mg tablets (Livial) and Prasterone 6.5mg pessaries (Intrarosa) to the list of Hormone
Replacement Therapy (HRT).
It has updated the June 2023 Drug Tariff (Part XVI) to include these additional HRT medicines for which patients will be able to purchase an HRT PPC.
"HRT is the replacement of female sex hormones oestrogen and progesterone in women to control symptoms of the menopause. Some medicines that are converted or break
down into oestrogen, progestogen or androgen hormones are prescribed for relief of menopausal symptoms. For the purposes of the HRT PPC these are included within
this definition of HRT," said DHSC.
The Department of Health and Social Care (DHSC) has introduced a new prescription pre-payment certificate (PPC) for Hormone Replacement Therapy (HRT) which
is said to benefit around 400,000 women who suffer from negative symptoms of the menopause in England.
PPC will be rolled-out from 1 April and it reduce the HRT costs to less than £20 a year. Women prescribed HRT - the main treatment for menopause symptoms - will
have access to a new scheme enabling access to a year's worth of menopause prescription items for the cost of two single prescription charges (currently £18.70).
As part of commitments to reduce the cost of HRT for menopausal women, the prescription PPC will be valid for 12 months. It can be used against a list of HRT
prescription items, and a patient can use this against an unlimited number of HRT items, such as patches, tablets and topical preparations. There will be no limit
to how many times the certificate can be used while it is valid.
"The introduction of the certificate delivers one of our year one priorities for the Women's Health Strategy for England. Published last summer, the strategy sets
out an ambitious new agenda for improving the health and wellbeing of women and girls and to improve how the health and care system listens to women. Menopause was
announced as a priority area within the strategy," said DHSC.
More than 500,000 women in England have benefitted from cheaper hormone replacement therapy (HRT) since the launch of the HRT prescription prepayment
certificates (PPC) on 1 April last year, according to the Department of Health and Social Care (DHSC).
HRT is the main treatment for negative menopause symptoms that can impact all areas of a woman's life.
Introduced as part of the government's Women's Health Strategy, which made menopause a priority area, the HRT PPC reduced prescription costs to just £19.30 per
year, helping patients save hundreds of pounds in prescription charges.
The DHSC has confirmed that more than £11 million was saved by women using the PPC in the last nine months.
Using the HRT PPC, patients can get a range of HRT items, including patches, tablets, and topical preparations at reduced prices, and they can use it many times
as needed throughout the year.
The Pharmaceutical Services Negotiating Committee (PSNC) has published a guidance for community pharmacies to help them in the implementation of the new
Prescription Prepayment Certificate (PPC) for hormone replacement therapy (HRT).
The new policy will rollout from 1 April 2023, patients who are not already exempt from NHS prescription charges will be able to purchase an annual HRT PPC for the
cost of two single prescription charges
Major concern raised by PSNC is that the NHS systems have not kept pace with policy, as the certificate is launching without the IT in place to support it.
PSNC has been clear that this is totally unacceptable, including raising this with Ministers directly and warning them that introducing the PPC without this
infrastructure risks causing confusion for some patients and adding to the burden for pharmacy teams.
"Government recognises the challenges but is determined to move forwards with the policy, said the committee. "DHSC has recognised the impact this will have on
pharmacies and we are still pressing for appropriate financial compensation. We have also sought guidance for GPs, and now published our own guidance to try to
make the launch go as smoothly as it can for pharmacy teams."
The new Hormone Replacement Therapy (HRT) prescription pre-payment certificate (PPC) has witnessed more than 37,000 purchases both via online website and
in-person in pharmacies since its launch on Saturday (1 April).
As of 12pm today (4 April), 37,240 HRT PPCs have been bought online and 501 in-pharmacy, totalling 37,741 certificates.
Department of Health and Social Care (DHSC) estimated women have saved over £1.13 million in prescription charges for the year, with the average person saving £30
for a year's supply.
The new prescription pre-payment certificate is also predicted to enable around 400,000 women to have cheaper access to menopause support.
On the launch of the scheme on Saturday, the huge demand for the much-anticipated certificate meant some patients were unable to access the website on the morning
of 1 April.
"The NHS Business Service Authority has ensured that the site has been working, allowing thousands of women to continue to successfully purchase a prescription for
a year's worth of hormone replacement therapy products which help treat the menopause," said DHSC.
Minister for Women's Health Strategy, Maria Caulfield said: "Over 37,700 women have come forward to claim cheaper HRT this weekend alone, showing what happens when we
listen to what women want.